A detailed history of Jpmorgan Chase & CO transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 27 shares of DMAC stock, worth $120. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27
Holding current value
$120
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$2.8 - $4.49 $75 - $121
27 New
27 $0
Q4 2023

Feb 12, 2024

BUY
$2.05 - $2.99 $1,104 - $1,611
539 Added 2156.0%
564 $1,000
Q3 2023

Nov 14, 2023

BUY
$2.56 - $4.4 $10 - $17
4 Added 19.05%
25 $0
Q2 2023

Aug 11, 2023

BUY
$1.53 - $4.4 $32 - $92
21 New
21 $0

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $118M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.